Related Experiment Videos
Treatment of Salmonella enteritis and its effect on the carrier state
Abstract:
During an outbreak of Salmonella enteritis, 113 symptomatic and asymptomatic patients were assigned to different treatment groups: 43 received ampicillin; 41 were given trimethoprim-sulfamethoxazole; and 29 received no specific therapy. During the four-week observation period no statistically significant benefit from treatment with either ampicillin or trimethoprim-sulfamethoxazole was apparent in relation to duration and severity of symptoms or duration of the carrier state. However, the impression that trimethoprim-sulfamethoxazole might have shortened the period of fecal Salmonella excretion in the few asymptomatic patients may warrant further controlled studies.There was no significant alteration in hematological or biochemical values, or urine constituents, in patients receiving trimethoprim-sulfamethoxazole. Side effects probably attributable to this drug developed in only 5% of the 41 patients.It is concluded that uncomplicated salmonellosis is best treated without using currently available chemotherapeutic agents.
Insights
For Salmonella enteritis, neither ampicillin nor trimethoprim-sulfamethoxazole showed significant benefits in symptom duration or severity. Uncomplicated salmonellosis is best treated without these specific chemotherapeutic agents.
Area of Science:
- Infectious Diseases
- Microbiology
- Pharmacology
Background:
- Salmonella enteritis outbreaks necessitate understanding effective treatment strategies.
- The efficacy of antibiotics like ampicillin and trimethoprim-sulfamethoxazole in salmonellosis requires evaluation.
Purpose of the Study:
- To assess the clinical effectiveness of ampicillin and trimethoprim-sulfamethoxazole in treating Salmonella enteritis.
- To compare the outcomes of antibiotic treatment versus no specific therapy for salmonellosis.
Main Methods:
- A clinical trial involving 113 patients (symptomatic and asymptomatic) with Salmonella enteritis.
- Patients were randomized into three groups: ampicillin, trimethoprim-sulfamethoxazole, or no specific therapy.
- A four-week observation period monitored symptom duration, severity, and carrier state.
Main Results:
- No statistically significant difference in symptom duration or severity was observed between treatment groups and the control group.
- Trimethoprim-sulfamethoxazole showed a potential, though not statistically significant, reduction in fecal Salmonella excretion in asymptomatic patients.
- Adverse effects of trimethoprim-sulfamethoxazole were minimal (5%), with no significant changes in hematological, biochemical, or urine values.
Conclusions:
- Current chemotherapeutic agents like ampicillin and trimethoprim-sulfamethoxazole do not offer significant benefits for uncomplicated salmonellosis.
- Treatment without specific antibiotics is recommended for uncomplicated salmonellosis.
- Further research into trimethoprim-sulfamethoxazole for asymptomatic carriers may be warranted.